Search Share Prices
Ixico wins expansions to two clinical trial contracts
Digital technologies company Ixico has won extensions to two contracts, expanding the clinical trial services it is providing to a pair of biopharmaceutical companies that will increasing the combined value of the contracts.
Ixico's contract changes reflect an "expansion in the scope" of its PET and MRI neuroimaging clinical trial services, with the AIM-quoted firm providing additional specialist services to the Phase II study contracts in Alzheimer's disease and Huntington's disease.
The changes to the contracts increased their combined value by roughly 24% to £2.35m.
Giulio Cerroni, chief executive of Ixico, said, "We are delighted to announce the expansion of these two contracts. This underscores the importance of working closely with our biopharmaceutical clients, particularly during the initial phase of a contract, to maximise the value our specialist technologies and services can provide".
As of 0900 BST, Ixico shares had grown 4.03% to 32.25p.